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Tumor-associated macrophages (TAMs) promote key processes in tumor progression, like angiogenesis,
immunosuppression, invasion, and metastasis. Increasing studies have also shown that TAMs can either
enhance or antagonize the antitumor efficacy of cytotoxic chemotherapy, cancer-cell targeting antibodies,
and immunotherapeutic agents—depending on the type of treatment and tumor model. TAMs also drive
reparative mechanisms in tumors after radiotherapy or treatment with vascular-targeting agents. Here, we
discuss the biological significance and clinical implications of these findings, with an emphasis on novel
approaches that effectively target TAMs to increase the efficacy of such therapies.Introduction
Macrophages phagocytose microbes and present antigens to
T cells, therefore constituting a first line of defense against
invading pathogens. They also regulate tissue growth, homeo-
stasis, repair, and remodeling via their expression of numerous
cytokines, chemokines, growth factors, proteolytic enzymes,
and scavenger receptors (Gordon and Martinez, 2010; Murray
and Wynn, 2011). As such, macrophages play a central role in
developmental processes, such as tissue morphogenesis and
vascular and neuronal patterning, but also in pathophysiological
responses, like inflammation and organ healing/regeneration
(Mantovani et al., 2013; Nucera et al., 2011; Pollard, 2009).
In selected organs of the adult mouse, the origin of tissue
macrophages can be traced back to fetal macrophages that
appear before the onset of definitive hematopoiesis (Schulz
et al., 2012). In inflamed and remodeling tissues, elevated
macrophage turnover is sustained largely from hematopoietic
progenitor cells (HPCs), which proliferate and differentiate into
promonocytes in the bone marrow (BM) before they are shed
into the circulation as monocytes. These then undergo final
differentiation into macrophages as they extravasate in the
target tissues (Shi and Pamer, 2011). During inflammation and
tumor growth, BM-derived HPCs may also accumulate at extra-
medullary sites, such as the spleen, which can become an
important site of monocyte production (Cortez-Retamozo
et al., 2012).
Once resident in tissues, macrophages acquire a distinct,
tissue-specific phenotype in response to signals present within
individual microenvironments. The exact combination of such
tissue-specific cues dictates both the differentiation and activa-
tion status of these cells. Two extreme forms of the latter are
generally referred to as ‘‘classical’’ (or M1) and ‘‘alternative’’ (or
M2) activation, which parallel Th1/Th2 programming of adaptive
immune cells (Biswas and Mantovani, 2010; Mantovani et al.,
2002). During acute inflammation, macrophages are M1-acti-
vated by toll-like receptor (TLR) agonists and Th1 cytokines
(e.g., interferon [IFN]-g). This enhances their ability to kill and
phagocytose pathogens, upregulate proinflammatory cytokines(e.g., interleukin [IL]-1b, IL-12, and tumor necrosis factor-a
[TNF-a]) and reactive molecular species, and present antigens
via major histocompatibility complex (MHC) class II molecules
(Biswas and Mantovani, 2010; Mantovani et al., 2002). Alterna-
tively, Th2 cytokines, like IL-4 and 13, stimulate monocytes/
macrophages to express an M2 activation state. This is charac-
terized by higher production of the anti-inflammatory cytokine,
IL-10; lower expression of proinflammatory cytokines; amplifica-
tion of metabolic pathways that can suppress adaptive immune
responses; and the upregulation of cell-surface scavenger
receptors, such as mannose receptor (MRC1/CD206) and
hemoglobin/aptoglobin scavenger receptor (CD163). As such,
M2macrophage activationmay facilitate the resolution of inflam-
mation and promote tissue repair (including angiogenesis) after
the acute inflammatory phase (Biswas and Mantovani, 2010;
Gordon and Martinez, 2010). In healthy tissues, macrophages
often express a mixed M1/M2 phenotype; hence ‘‘M1’’ and
‘‘M2’’ polarization should be regarded as extreme ends of
a continuum of activation states, with their exact point on the
scale depending on the precise mix of local signals present in
a given microenvironment (Biswas and Mantovani, 2010; Law-
rence and Natoli, 2011; Sica and Mantovani, 2012).
Tumor-Associated Macrophages
Macrophages are a major cellular component of murine and
human tumors, where they are commonly termed tumor-associ-
ated macrophages (TAMs). In this article, we specifically review
the role of these cells and their monocyte precursors in tumor
responses to anticancer therapies. Other tumor-infiltrating
myeloid cells not discussed here include neutrophils, eosino-
phils, and activated dendritic cells (DCs) (de Visser et al.,
2006). Tumors also recruit a variety of immature myeloid cells,
often referred to as myeloid-derived suppressor cells (MDSCs),
which comprise precursors of both the monocyte-DC (mononu-
clear) and neutrophil (granulocytic) lineages and are commonly
identified by their expression of Gr1 (Ly6C/G) and immunosup-
pressive activity. Mononuclear MDSCs can further mature
into TAMs (Coffelt et al., 2010; Gabrilovich et al., 2012). Finally,Cancer Cell 23, March 18, 2013 ª2013 Elsevier Inc. 277
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cells homing to tumors and modulating tumor progression
(Shaked and Voest, 2009).
Various mouse studies have shown that monocytes are re-
cruited into tumors in large numbers by chemokines secreted
by both malignant and stromal cells. These include chemokine
(C-C motif) ligand 2 (CCL2, or MCP1), colony-stimulating
factor-1 (CSF1), and chemokine (C-X-C motif) ligand 12
(CXCL12, or SDF1) (Murdoch et al., 2008). Upon monocyte
differentiation into TAMs, these cells act as a source of local
and systemic cues to support the proliferation, survival, and
motility of the cancer cells; tumor vascularization (angiogenesis);
suppression of antitumor immunity; and intravasation of cancer
cells at the primary tumor site and extravasation/growth at
distant metastatic sites (Bingle et al., 2006; De Palma et al.,
2003; DeNardo et al., 2009; Lewis and Pollard, 2006; Lin
et al., 2001; Qian et al., 2011; Qian and Pollard, 2010; Ruffell
et al., 2012a; Squadrito and De Palma, 2011; Wyckoff et al.,
2004). This impressive array of tumor-promoting functions is
consistent with clinical studies showing high macrophage
density in many human cancer types to be associated with
increased tumor angiogenesis and metastasis, and/or a poor
prognosis (Bingle et al., 2002; Clear et al., 2010; Heusinkveld
and van der Burg, 2011; Leek et al., 1996). Furthermore, enrich-
ment of a macrophage-related gene signature correlates with
reduced survival in some types of human cancer (Engler et al.,
2012; Steidl et al., 2010).
A decade ago, it was proposed that TAMs are predominantly
polarized in the tumor microenvironment toward an M2-like
phenotype and that this underlies their ability to promote the
growth and vascularization of tumors (Mantovani et al., 2002).
This is also supported by clinical studies showing the predictive
value of M2-macrophage associated markers, like CD163
(Heusinkveld and van der Burg, 2011). Flow cytometry and
gene expression profiling of mouse and human TAMs has
shown that distinct macrophage subpopulations with a variably
skewed M2-like phenotype coexist in tumors and that their
relative abundance varies with the tumor type (Movahedi et al.,
2010; Pucci et al., 2009; Ruffell et al., 2012b). Such complexity
likely indicates diverse TAM programming in different micro-
environments within individual tumors (Lewis and Pollard,
2006; Qian and Pollard, 2010; Ruffell et al., 2012a; Squadrito
and De Palma, 2011). For example, M2-like TAMs reside in
both perivascular and hypoxic regions of different mouse and
human tumors (Mazzieri et al., 2011;Movahedi et al., 2010; Pucci
et al., 2009). A population of vessel-associated TAMs—also
referred to as TIE2-expressing monocytes/macrophages
(TEMs)—is required for tumor angiogenesis (De Palma et al.,
2005) and displays a profoundly M2-skewed phenotype charac-
terized by enhanced expression of scavenger receptors (e.g.,
MRC1 and CD163) and relatively low levels of MHCII molecules
and proinflammatory cytokines (Pucci et al., 2009; Squadrito
et al., 2012). Interestingly, vascular endothelial cells (ECs) may
induce HPCs to directly differentiate into TIE2+MRC1+ macro-
phages in the perivascular microenvironment, a process that
appears to depend on EC-derived CSF1 (He et al., 2012). Also
attesting to the complexity of TAM subtypes, recent studies
have shown that both the origin and phenotype of TAMs may
differ in primary versus metastatic tumors (Qian et al., 2011).278 Cancer Cell 23, March 18, 2013 ª2013 Elsevier Inc.TAMs with a relatively M1-skewed phenotype may be found in
incipient or regressing tumors as well as necrotic areas of pro-
gressing tumors (Prada et al., 2013; Wang et al., 2011). Gene
expression profiling of M1- and M2-like TAMs, however,
suggests that such TAM ‘‘subtypes’’ express both canonical
M1 andM2markers, albeit at significantly different levels (Mova-
hedi et al., 2010; Pucci et al., 2009; Squadrito et al., 2012).
Macrophage Involvement in Tumor Responses to
Therapy
As will be seen below, TAMs not only enhance tumor growth and
progression, but also modulate the efficacy of various forms of
anticancer therapy. In some circumstances, they also facilitate
tumor regrowth, revascularization, and spread after the treat-
ment.
Chemotherapy
A complex picture has emerged over the past 30 years of the role
of TAMs in modulating the antitumor efficacy of chemothera-
peutic agents (Figure 1). Early studies showed that the antitumor
efficacy of doxorubicin (DOX; an anthracycline formerly known
as adriamycin) is reduced when mice bearing immunogenic
leukemia or lymphoma transplants were given macrophage
toxins (Mantovani et al., 1979; Figure 1A). Furthermore, the in vivo
administration of DOX enhanced the tumoricidal activity of
macrophages ex vivo. Interestingly, macrophages did not
enhance the efficacy of DOX against poorly immunogenic
lymphomas, suggesting that tumor immunogenicity may influ-
ence the ability of macrophages to modulate the antitumor
activity of DOX. In contrast, macrophage depletion failed to limit
the antitumor activity of another anthracycline, daunorubicin
(formerly daunomycin) (Mantovani et al., 1979), possibly because
the latter is per se toxic toward macrophages in vivo (Mantovani,
1977). Together, these early reports suggested that some cyto-
toxic agents are able to foster the antitumor activities of TAMs,
at least in leukemia and/or immunogenic (transplant) tumor
models. In this regard, innate immune cells, like macrophages
and DCs, are known to mediate ‘‘immunogenic cell death’’
(ICD), a process that encompasses chemotherapy-induced
cancer cell death and release of ‘‘eat-me’’ signals (e.g., ATP
and high-mobility groupB1 [HMGB1]); activation ofmononuclear
phagocytes and enhancement of their antigen-presenting
capacity; and promotion of T cell responses against immuno-
genic tumors. Of note, only a few chemotherapeutics are known
to induce ICD, one of which is DOX (Kroemer et al., 2012).
TAMs can also contribute in other ways to the modulation of
tumor responses to chemotherapy. Figure 1 shows that this
can vary markedly between different cytotoxic agents and
tumor models. For example, the antitumor activity of the taxane
docetaxel involves the depletion of immunosuppressive (M2-
like) TAMs and the concomitant activation or expansion of anti-
tumoral (M1-like) monocytes/MDSCs in 4T1-Neu mammary
tumor implants. Indeed, in vitro T cell assays showed that
docetaxel-treated monocytes/MDSCs are able to enhance
tumor-specific, cytotoxic T cell responses (Kodumudi et al.,
2010). Trabectedin, a DNA-damaging agent approved for soft
tissue sarcomas, inhibited the growth of mouse fibrosarcomas
primarily by depleting mononuclear phagocytes, including
monocytes and TAMs (Germano et al., 2013). Mechanistically,
it activates caspase 8 and induces apoptosis specifically in
Figure 1. TAMs Enhance or Limit the Efficacy of
Chemotherapy Depending on the Cytotoxic Agent
Applied and/or Mouse Tumor Model Used
(A) Chemosensitivity is increased when cytotoxic agents, either
directly or indirectly, increase the cytotoxicity of TAMs or
deplete monocytes, TAMs, or M2-like TAMs. The latter cells can
also be reprogrammed by agents like HRG, which in turn
enhances chemotherapy delivery. DOX enhances the cytotox-
icity of macrophages/TAMs, a process possibly involving ICD
(top); DOC promotes the expansion of cytotoxic M1-like
MDSCs/TAMs, which enhance antitumor T cell responses
(right); TRAB depletes protumoral monocytes/TAMs via cas-
pase-8 activation (bottom); HRG downregulates PlGF in TAMs,
reprogramming them toward an M1-like phenotype, and
enhances DOX delivery (left).
(B) Chemoresistance is increased when cytotoxic agents, either
directly or indirectly, increase protumoral (M2-like) TAM
numbers. The latter cells may also limit chemotherapy delivery
by affecting vascular leakage. DOX enhances tumor infiltration
byMMP9-expressingmonocytes via upregulation of CCL2 (top);
PTX enhances tumor infiltration by macrophages via upregula-
tion of CSF1 (right); PTX, GEM, and 5FU enhance tumor infil-
tration by cathepsin-B/S-expressing monocytes/macrophages,
which activate chemoprotective T cells through IL-1b and 17
(bottom); VEGF-expressing TAMs augment vascular leakiness
and limit CTX delivery (left).
Abbreviations: DOC, docetaxel; TRAB, trabectedin; CTX,
cyclophosphamide; GEM, gemcitabine; 5-FU, 5-fluorouracil;
IL-1b, interleukin-1b; IL-17, interleukin-17.




Reviewmonocytes/macrophages via TRAIL-R2, a death receptor not
expressed by other leukocytes. Interestingly, trabectedin also
depleted circulating monocytes and TAMs in patients with
soft-tissue sarcomas. These findings support the notion that
the antitumor activity of some cytotoxic agents may depend, at
least in part, on their ability to reprogram or deplete protumoral
mononuclear phagocytes (Kodumudi et al., 2010; Germano
et al., 2013). It remains to be seen whether the mode of action
of trabectedin also entails the promotion of adaptive antitumor
immune responses, unleashed through the depletion of immuno-
suppressive TAMs (Figure 1A).
There is also compelling evidence for TAMs limiting the effi-
cacy of chemotherapy (Figure 1B). For example, TAM depletion
by anti-CSF1 antibodies enhanced the efficacy of combination
chemotherapy (cyclophosphamide, methotrexate, and 5-fluoro-
uracil) in chemoresistant, human breast cancer xenografts
grown in immunodeficient mice (Paulus et al., 2006). Similarly,
TAM depletion enhanced the efficacy of paclitaxel (PTX, a tax-
ane) in immunocompetent, MMTV-PyMT mouse mammary
tumors (DeNardo et al., 2011). At variance with some other cyto-
toxic drugs (e.g., trabectedin), PTX did not affect tumor growth
by depleting TAMs. Rather, it augmented their recruitment to
the tumors by upregulating tumor-derived CSF1. Consistent
with the known immunosuppressive functions of TAMs, the
increased TAM numbers in PTX-treated tumors limited tumor
infiltration by CD8+ cytotoxic T cells and possibly reduced their
tumoricidal activity. These important findings suggest that
TAMs may limit the therapeutic activity of PTX in breast cancer,
at least in part, by suppressing specific antitumor immune
responses (DeNardo et al., 2011).
TAMs may also release ‘‘chemoprotective’’ factors. Shree
et al. (2011) reported increased TAM numbers in PTX-treated
MMTV-PyMT tumors and showed that TAM secretion of the
lysosomal enzymes, cathepsins B and S, protected cancer cells
from PTX-induced cell death and so limited the efficacy of this
agent (Shree et al., 2011). Indeed, a pan-cathepsin inhibitor
improved the response of MMTV-PyMT tumors to PTX. Interest-
ingly, coculture experiments showed that such macrophage-
derived cathepsins protect cancer cells from the direct cytotoxic
effects of several chemotherapeutics, including DOX and etopo-
side (Shree et al., 2011). In this regard, a recent study showed
that two broadly used chemotherapeutics, gemcitabine and
5-fluorouracil, induce monocytes/MDSCs to release cathepsin
B from lysosomes (Bruchard et al., 2013). This activates the
inflammasome and enhances monocyte/MDSC secretion of
IL-1b. In turn, IL-1b prompted secretion of IL-17 by CD4+
T cells, which then blunted the anticancer effects of chemo-
therapy (Figure 1B). These data provide a molecular mechanism
linking myeloid cell-derived cathepsins to chemoprotection.
While DOX may stimulate macrophage cytotoxicity toward
immunogenic leukemias (Mantovani et al., 1979), its effects on
TAMs appear to vary with the tumor type. In the transgenic
MMTV-PyMTmammary tumor model, DOX induction of necrotic
cell death led to increased tumor infiltration by CCL2 receptor
(CCR2)+ monocytes/TAMs, a process that relied on upregulation
of CCL2 (Nakasone et al., 2012). Interestingly, the antitumor
activity of DOX was enhanced in Ccr2 knockout hosts, which
lack CCR2+ monocytes. While the effect of DOX on the cytotoxic
activity of TAMs was not examined in this study, the authors280 Cancer Cell 23, March 18, 2013 ª2013 Elsevier Inc.showed that matrix-metalloproteinase (MMP)-9 produced by
recruited myeloid cells decreased blood vessel leakiness and
limited drug delivery to the tumors, suggesting that, at least in
MMTV-PyMT tumors, increased vascular permeability is associ-
ated with a better response to DOX (Nakasone et al., 2012). It
should be noted that, in other tumor models, downregulating
the expression of proangiogenic factors, like vascular endothe-
lial growth factor (VEGF) or placental growth factor (PlGF)
by TAMs ‘‘normalized’’ the tumor-associated vasculature, de-
creased vessel leakiness, and enhanced chemotherapy delivery
to tumors (Rolny et al., 2011; Stockmann et al., 2008; Figures 1A
and 1B). It remains to be seen whether the different effects of
DOX in leukemia versus the above mammary tumor model
(Nakasone et al., 2012) reflect differences in tumor immunoge-
nicity or more complex aspects of the tumor microenvironment.
Taken together, the above studies show that different chemo-
therapeutic agentsmay induce distinct responses inmonocytes/
macrophages, which can either enhance or antagonize the
activity of the anticancer drug, possibly in a tumor-type depen-
dent fashion. Tumor immunogenicity along with the intrinsic
sensitivity of TAMs to the drug and their activation state (M1
versus M2-like) may be important determinants of such TAM-
mediated responses. Furthermore, cytotoxic drugs often target
multiple cell types in tumors, so tumor-type specific stromal
cell signatures (Coussens et al., 2013) could influence the ability
of TAMs to respond to and modulate the activity of a given
chemotherapeutic. Indeed, cytotoxic drugs could have both
direct and indirect effects on TAM behavior. For example, tax-
anes profoundly alter macrophage gene expression in vitro
(Javeed et al., 2009) but also induce tumor damage and cancer
cell death, which may trigger a reparative, ‘‘wound healing’’
response in TAMs (Mantovani et al., 2013). Further studies are
now warranted to distinguish between the role of TAMs in the
chemoprotection described above (DeNardo et al., 2011; Naka-
sone et al., 2012; Shree et al., 2011) and the reparative
responses that occur in tumors after therapy.
Finally, TAMs may enhance tumor chemoresistance by
providing survival signals to tumor-initiating/cancer stem cells
(CSCs). For example, TAMs were found to release milk fat
globule-epidermal growth factor 8 protein (MFG-E8) to help
protect lung and colon CSCs from cisplatin. This relied, at least
in part, on MFG-E8-induced activation of STAT3, which
enhanced CSC chemoresistance (Jinushi et al., 2011). More-
over, TAM depletion has been shown to improve antitumor
T cell responses and the efficacy of chemotherapy in a pancre-
atic cancer model, in part by decreasing the frequency, tumor-
initiating capacity, and STAT3 activation of CSCs (Mitchem
et al., 2013).
Tumor Irradiation
Tumor irradiation is widely used to treatmany cancer types. Early
studies correlated high TAM numbers inmouse tumors with poor
tumor responses to irradiation (Milas et al., 1987). Recent data
suggest that radiation-induced DNA damage and activation of
the v-abl Abelson murine leukemia viral oncogene homolog 1
(ABL1) kinase promote Csf1 gene transcription and upregulation
of tumor CSF1, which in turn recruits CSF1R-expressingmyeloid
cells (including TAMs) that enhance posttherapy tumor regrowth.
Indeed, a CSF1R inhibitor improved tumor response to radio-
therapy in a prostate cancer model (Xu et al., 2013; Figure 2).
Figure 2. TAMs Promote Tumor Regrowth
Following Tumor Irradiation,
Antiangiogenic Drugs and VDAs
These anticancer therapies cause tumor necrosis,
vascular damage, and hypoxia, which together
or separately induce the upregulation of several
myeloid cell/monocyte chemoattractants, in-
cluding CXCL12, CSF1, CSF3, VEGF, and ANG2,
in the tumor microenvironment. De novo recruit-
ment of myeloid cells drives tumor regrowth via
their effects on the tumor blood vessels (mediated,
e.g., by MMP9, Bv8, and IGF1) and, possibly, the
cancer cells.
Abbreviations: CSF3, granulocyte-colony stimu-
lating factor; Bv8, prokineticin.
See also Figure 1.
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human head and neck tumors grown in immunodeficient mice
also reduced tumor regrowth after therapy (Ahn et al., 2010). In
a model of orthotopic human glioblastoma, local irradiation
dramatically enhanced tumor infiltration byCD11b+myeloid cells
(Kioi et al., 2010). Interestingly, a high proportion of these cells
were F4/80+TIE2+ TEMs, and their recruitment was dependent
on the hypoxic induction of the chemoattractant, CXCL12, in
the irradiated tumors (Figure 2). Upregulation of CXCL12 and
increased TEM infiltration were also observed in lung and
mammary tumors grown subcutaneously following irradiation
(Kozin et al., 2010). In the latter study, TEMs congregated mainly
around the remaining blood vessels in treated tumors (Kozin
et al., 2010), suggesting that they may stimulate tumor recur-
rence by promoting EC survival and vascular regrowth through
their expression of prosurvival factors like insulin growth factor
1 (IGF1) and fibroblast growth factor 2 (FGF2) (De Palma et al.,
2005; Pucci et al., 2009). However, the location and, possibly,
the function of M2-like TAMs in irradiated tumors may vary with
tumor type. In irradiated orthotopic astrocytomas, arginase-1
(ARG1)+M2-like TAMswere found to accumulate mainly in avas-
cular, hypoxic areas rather than at perivascular sites (Chiang
et al., 2012). This suggests that the reparative mechanisms em-
ployed by M2-like TAMs in postirradiated tumors may be regu-
lated by distinct microenvironmental signals in different tumor
types. It is also conceivable that the functions of M2-like TAMs
in irradiated tumors are similar to those of M2-like macrophages
driving tissue repair in healing organs, such as following acute
renal injury and myocardial infarction (Mantovani et al., 2013).
Vascular-Targeted Therapies
VEGF is a proangiogenic cytokine that also functions as a potent
monocyte chemoattractant (Barleon et al., 1996). It is, therefore,
possible that the antiangiogenic and antitumor effects of
VEGF blockade could result, at least in part, from impairedCancer Cell 2monocyte/TAM recruitment. However,
this seems increasingly unlikely, as it is
now established that therapeutic inter-
ception of VEGF is counteracted by the
compensatory induction of other proan-
giogenic factors, some of which are
involved in monocyte/myeloid cell che-
moattraction (Bergers and Hanahan,
2008; Ferrara, 2010).Tumor hypoxia and necrosis dramatically increase after the
selective destruction of tumor blood vessels by high-dose anti-
angiogenic drugs or vascular-disrupting agents (VDAs) (Bergers
and Hanahan, 2008). When tumors are treated with VDAs, like
combretastatin-A4-phosphate (CA-4-P), the selective disruption
of the tumor-associated vasculature results in vessel collapse,
reduced blood flow, induction of tumor hypoxia, and secondary
tumor cell death. As in irradiated tumors, VDA-induced hypoxia
was associated with elevated levels of CXCL12 and increased
TEM infiltration in mammary tumor models (Welford et al.,
2011; Figure 2). Blocking this CA-4-P-induced TEM recruitment,
either using the CXCR4 antagonist, plerixafor (AMD3100), or
by genetic TEM depletion, markedly increased the efficacy of
CA-4-P treatment in subcutaneous N202 (Neu+) mammary carci-
nomas (Welford et al., 2011).
Blocking the proangiogenic factor angiopoietin-2 (ANG2) also
leads to angiogenesis inhibition and increased tumor hypoxia
(Daly et al., 2013; Mazzieri et al., 2011). As seen in CA-4-P-
treated tumors (Welford et al., 2011), the latter events were asso-
ciated with an enhanced recruitment of MRC1+ TEMs, which
may have limited the efficacy of ANG2 blockade (Mazzieri
et al., 2011). Sorafenib, which targets several receptor tyrosine
kinases (including VEGF receptor 2 [VEGFR2] and platelet-
derived growth factor receptor [PDGFR]) and Raf kinases, was
also shown to increase CXCL12 levels and TAM infiltration in
hepatocellular carcinoma xenografts. Depletion of TAMs by
clodronate-loaded liposomes (clodrolip) augmented the inhibi-
tory effects of sorafenib on tumor angiogenesis, growth, and
metastasis in this tumor model (Zhang et al., 2010). Moreover,
TAM depletion by clodrolip (Zeisberger et al., 2006) or a
CSF1R inhibitor (Priceman et al., 2010) increased the antiangio-
genic and antitumor effects of VEGF/VEGFR2 antibodies in
subcutaneous tumor models. Together, these data support the
rationale for combining antiangiogenic drugs with macrophage3, March 18, 2013 ª2013 Elsevier Inc. 281
Figure 3. moAbs Activate TAMs to Express a Cytotoxic Phenotype
Binding of therapeutic antibodies to monocytes/macrophages may enhance their tumoricidal activity.
(A) Binding of therapeutic (cancer-cell targeted) moAbs (e.g., anti-HER2) to monocytes/TAMs via Fc-receptors (FcRs) induces FcR-mediated activation of
macrophage cytotoxicity/phagocytosis (ADCC/ADCP) and priming of adaptive antitumor immunity (e.g., CD8+ T cells).
(B) Binding of immunotherapeutic moAbs (e.g., anti-CD40) to monocytes/TAMs triggers their activation to a cytotoxic (M1-like) phenotype.
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ularly in tumors that are refractory or develop resistance to anti-
VEGF therapy.
Targeted Therapies by Monoclonal Antibodies
Although a role for TAMs inmodulating the efficacy of oncogene-
targeted, small molecule inhibitors has yet to be elucidated,
there is now increasing evidence for TAMs contributing to the
cytotoxicity of therapeutic monoclonal antibodies (moAbs).
TAMs express surface receptors that bind the Fc fragment of
antibodies and enable them to engage in Ab-dependent cellular
cytotoxicity/phagocytosis (ADCC/ADCP). Trastuzumab, a moAb
against the human epidermal growth factor receptor-2 (HER2),
not only interrupts HER2 signaling in breast cancer cells,
thereby slowing their proliferation rate, but also induces Fcg
receptor (FcgR)-mediated activation of macrophage cyto-
toxicity (Clynes et al., 2000) and priming of antigen-specific
CD8+ T cell responses in MMTV-Neu tumors (Park et al., 2010)
(Figure 3A). In one study, TAM depletion limited the efficacy of
a moAb directed against tissue factor (CD142)-expressing
human breast carcinoma cells inoculated in mice (Grugan
et al., 2012). Macrophages also enhance lymphoma elimination
in mice in response to rituximab, a moAb against CD20, primarily282 Cancer Cell 23, March 18, 2013 ª2013 Elsevier Inc.through FcgR-dependent ADCP (Chao et al., 2010; Minard-Colin
et al., 2008). The significance of the aforementioned studies is
supported by clinical findings suggesting that certain FCGR
polymorphismsmay bear predictive value for the clinical efficacy
of trastuzumab or rituximab therapy in breast cancer and
lymphoma, respectively (Mellor et al., 2013). Furthermore, high
TAM numbers correlate with a better prognosis in rituximab-
treated patients (Taskinen et al., 2007). Engineered recombinant
proteins that can enhance the interactions between FcgR-ex-
pressing immune cells and moAbs, like the recently described
‘‘grababodies’’ (Cai et al., 2013), may thus have the potential to
increase ADCC/ADCP in tumors. It should be noted, however,
that engagement of macrophage-FcgRs by serumor therapeutic
antibodies (e.g., the anti-EGFR moAb cetuximab) was shown to
enhance the immunosuppressive, proangiogenic, and protu-
moral functions of TAMs both in experimental tumor models
and human cancer (Andreu et al., 2010; Pander et al., 2011).
Immunotherapies
As mentioned previously, TAMs can be potent immunosuppres-
sors that limit the cytotoxic activity of CD8+ cytotoxic T cells in
progressing tumors (DeNardo et al., 2011). The analysis of
human breast cancer tissues showed that a high stromal TAM
Cancer Cell
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et al., 2011). In a preclinical study, clodrolip-mediated depletion
of TAMs enhanced tumor infiltration by HPV16 E7-specific CD8+
T cells in a HPV16 E6+/E7+ mouse model of cervical cancer
(Lepique et al., 2009). TAM-mediated immunosuppression is
mediated, at least in part, by induction of T cell apoptosis and
nitrosylation of T cell receptors via macrophage products, like
ARG1, NOS2, and peroxynitrite (Gabrilovich et al., 2012).
It should be noted that the study by DeNardo et al. (2011)
analyzed the leukocyte composition of established tumors (De-
Nardo et al., 2011), in which immunosuppressive, M2-like
TAMs likely predominate over tumoricidal (M1-like) macro-
phages. It is possible that incipient tumors, which are likely to
be more immunogenic than established lesions, contain higher
proportions of M1-like TAMs, which could initiate and/or poten-
tiate adaptive immune responses (Prada et al., 2013;Wang et al.,
2011). In this regard, macrophages were shown to acutely engulf
myeloma cells inoculated subcutaneously in syngenic mice and
to activate myeloma-specific CD4+ Th1 cells, which then
enhanced the tumoricidal activity of macrophages through
IFN-g secretion (Corthay et al., 2005). In certain immunoprivi-
leged organs, such as the eye, macrophages promote the
effector functions of CD4+ T cells, and their depletion enhances
rather than inhibits intraocular tumor growth (Dace et al., 2008).
Thus, the type of macrophage activation—which may correlate
with tumor stage (Prada et al., 2013; Wang et al., 2011)—may
dictate the magnitude of antitumoral T cell responses in mouse
models of cancer.
Based on the above, strategies to deplete TAMs or block
cancer-induced M2-like macrophage programming (see below)
may have the potential to enhance T cell-mediated antitumor
responses and improve the efficacy of immunotherapies (Cous-
sens et al., 2013; Hagemann et al., 2008; Jaiswal et al., 2010).
Intriguingly, increasing data suggest that the efficacy of some
forms of immunotherapy may also depend on effective reprog-
ramming of TAMs toward an M1-like phenotype. For example,
intravesical instillation of Mycobacterium bovis bacillus Calm-
ette-Gue´rin, which is used for the treatment of superficial
bladder cancer, reduces tumor recurrence by stimulating the
cytotoxic activity of macrophages. Macrophage-mediated killing
of bladder cancer cells relies on both direct effector-target cell
contacts and the release of soluble cytotoxic factors, such
as TNF-a, IFN-g, and NO, from the macrophages (Luo and
Knudson, 2010). An agonistic antibody to the TNF receptor
superfamily member, CD40, was recently reported to bind to
circulating monocytes, trigger their recruitment into mouse
pancreatic tumors, and activate their tumoricidal functions
(Figure 3B). These CD40-activated, cytotoxic (M1-skewed)
TAMs were also found to enhance the efficacy of gemcitabine
in a small cohort of patients with surgically incurable pancreatic
cancer (Beatty et al., 2011). Finally, macrophages and DCs
express programmed cell death ligand-1 (PDL1, also known as
B7-H1), a major negative regulatory ligand that suppresses
T cell activation through its receptor-programmed cell death
protein 1. The promising therapeutic activity of anti-PDL1moAbs
in patients with advanced cancer (Brahmer et al., 2012) will
no doubt prompt further studies of the possible inhibition of
PDL1 expression on TAMs to improve the efficacy of chemo-
or antiangiogenic therapies.Concluding Remarks: Implications for Cancer
Treatment
In light of this growing body of evidence for TAMsmodulating the
effects of various anticancer therapies, attempts are now being
made to either target key molecules that regulate their recruit-
ment into tumors or re-educate these cells toward a cytotoxic
M1-like phenotype. The efficacy of CSF1R inhibitors in blocking
the enhanced uptake of monocytes during PTX treatment in
preclinical studies (DeNardo et al., 2011) has prompted clinical
trials of their use in combination with either PTX or the antiproli-
ferative agent eribulin (http://www.clinicaltrials.gov). Various
preclinical studies have also highlighted ways to reprogram
TAMs from an M2 to an M1-like phenotype in tumors. These
include the use of histidine-rich glycoprotein (HRG), which
induces macrophage downregulation of PlGF, promotes the
normalization of blood vessels, and increases delivery and effi-
cacy of chemotherapy in mouse tumor models (Rolny et al.,
2011; Figure 1A). Other strategies to reprogram TAMs include
blockade of nuclear factor-kB signaling (Hagemann et al.,
2008) or their exposure to anti-IL-10R antibodies combined
with the TLR9 ligand CpG (Guiducci et al., 2005). The latter re-
sulted in hemorrhagic tumor necrosis, activation of DCs and
cytotoxic T cells, and clearance of tumor remnants.
However, there is still much to learn about the mechanisms
regulating TAM functions during chemotherapy, as well as other
forms of therapy discussed in this review. Importantly, a number
of key questions need to be addressed before approaches that
combinemacrophage targeting (or reprogramming) and conven-
tional cancer therapies can be translated into more effective
treatments. Why do preclinical studies employing distinct
chemotherapeutic drugs and/or tumor models show different
and, at times, contradictory roles for TAMs in modulating tumor
responses to such agents? Why do TAMs apparently limit the
effects of chemotherapy in some tumor types but not others?
Are the distinct TAM subtypes present in individual tumors differ-
entially responsive to chemotherapy? If yes, what are the
specific features of the TAM subset(s) that either enhance or
promote the antitumor activity of cytotoxic agents? And what
are the signals in tumors that regulate these TAM responses?
Such informationmight help selectively target the TAMs that limit
chemotherapy while leaving antitumoral or tissue-resident
macrophages unaffected. Furthermore, most preclinical studies
to date have focused on primary, nonmetastatic tumors. So, are
we confident that TAMs in metastatic tumors (Qian et al., 2011)
behave in the same way during therapy as those in the primary
tumor site?
Mouse tumor models, including genetically engineeredmouse
models (GEMMs), are being used extensively to study mecha-
nisms underlying tumor (and TAM) responses to anticancer ther-
apies. However, even sophisticated GEMMs of cancer cannot
simulate the endless variations in TAM abundance, distribution,
and phenotypes between and within different types and
subtypes of human cancer (Coussens et al., 2013; De Palma
and Hanahan, 2012). Nor do they necessarily model the ability
of such tissues to recruit monocytes during therapy. Future
work should therefore aim to define the identities and molecular
profiles of distinct TAM subtypes in human cancer biopsies
before, during, and after therapy. Specific TAM signatures could
then be used to stratify patients carrying defined genetic lesionsCancer Cell 23, March 18, 2013 ª2013 Elsevier Inc. 283
Cancer Cell
Reviewin order to explore how such signatures correlate with the
response of individual patients to chemo-, radio-, or targeted
therapies, and/or the emergence of secondary resistance
(DeVita and Costa, 2010). If such studies demonstrate the
predictive value of specific TAM subtypes for individual tumor
responses, then their further characterization in mouse tumor
models could help develop more effective cancer therapies.
Undeniably, such clinical approaches should consider the
biological complexities on a tumor (sub)type and individual
patient basis and harness them to design effective personalized
therapies.
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